Novel steroidal 1,3,4-thiadiazines: Synthesis and biological evaluation in androgen receptor-positive prostate cancer 22Rv1 cells
作者:Anna S. Komendantova、Alexander M. Scherbakov、Alexander V. Komkov、Viktoriya V. Chertkova、Alexey O. Gudovanniy、Elena I. Chernoburova、Danila V. Sorokin、Yaraslau U. Dzichenka、Valerii Z. Shirinian、Yulia A. Volkova、Igor V. Zavarzin
DOI:10.1016/j.bioorg.2019.103142
日期:2019.10
A flexible approach to previously unknown spirofused and linked 1,3,4-thiadiazine derivatives of steroids with selective control of heterocyclization patterns is disclosed. (N-Arylcarbamoyl)spiroandrostene-17,6′ [1,3,4]thiadiazines and (N-arylcarbamoyl)17-[1′,3′,4′]thiadiazine-substituted androstenes, novel types of heterosteroids, were prepared from 16β,17β-epoxypregnenolone and 21-bromopregna-5,16-dien-20-one
公开了一种对甾体的以前未知的螺合的和连接的1,3,4-噻二嗪衍生物具有选择性控制杂环化模式的灵活方法。(N-芳基氨基甲酰基)螺雄甾烯17,6'[1,3,4]噻二嗪和(N-芳基氨基甲酰基)17- [1',3',4']噻二嗪取代的雄烯酮是由新型杂类固醇制备的16 β,17 β -epoxypregnenolone和21 bromopregna -5,16-二烯-20-酮在良好至高产率通过用草氨酸硫代酰肼的治疗。筛选合成的化合物对人雄激素受体阳性前列腺癌细胞系22Rv1的抗增殖活性。大部分(N-芳基氨基甲酰基)17- [1',3',4']噻二嗪取代的雄烯酮显示出 比抗雄激素比卡鲁胺更好的抗增殖能力(IC 50 = 2.1–6.6 µM)。 在研究的系列中,IC 50 = 3.0μM的化合物7d和IC 50 = 2.1μM的化合物7j被证明是活性最高的。铅合成的化合物7j下调22Rv1细胞中AR